Skip to content

A Randomized, Double-blinded and Placebo-controlled Multicenter Phase III Clinical Trial to Confirm the Efficacy and Safety of Qingfeng Ganke Granules in the Treatment of Postinfectious Cough(Wind-evil Loving Lung Syndrome):Cough Resolution Duration as Primary Outcome

Qingfeng Ganke Granules in the Treatment of Postinfectious Cough(Wind-evil Loving Lung Syndrome): a Randomized, Double-blinded and Placebo-controlled Multicenter Phase III Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003278
Enrollment
Unknown
Registered
2013-06-14
Start date
2013-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postinfectious Cough

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients meet the diagnosis standard of postinfectious cough; 2. The TCM classification is wind-evil loving lung syndrome; 3. Score of cough during day >=2 and/or score of cough during night>=2; 4. Cough duration is from 3-6 weeks; 5. Aged 18 to 65 years old; 6. Patients voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Body temperature higher than 37.3 degree C; 2. Patients who use drugs to treat postinfectious cough in last one week; 3. ALT or AST> 1.5 times of upper limit, abnormal serum creatitine, white blood cell count10*10^9/L, and/or N>80%; 4. Patients with a serious primary cardio-cerebrovascular, liver, kidney, or hematological disease, or otherserious diseases affected the survival, such as cancer or AIDS; 5. Pregnant or lactating women, or women who have birth plan; 6. Allergic constitution or be allergy to the drug composition used in the trial; 7. Mental illness; 8. Patients who is participating or participated in last 3 months in other drug clinical trials.

Design outcomes

Primary

MeasureTime frame
resolution duration of coug;

Secondary

MeasureTime frame
response duration of cough;decrease of cough score;disappearance rate of cough;the Chinese medicine symptom curative effect;

Countries

China

Contacts

Public ContactMao Bing
maobing@medmail.com.cn+86 18980601724

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 4, 2026